Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nilay Bakoglu Malinowski has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Nuclear SOX9 Expression and Short-Term Survival Outcomes in Early-Stage Luminal Breast Cancer: An Immunohistochemical and Retrospective Cohort Analysis

    by Ebru Karci, Sabin Goktas Aydin, Osman Erinc, Taskin Erkin Uresin, Sevinc Dagistanli, Nilay Bakoglu Malinowski, Ahmet Aydın, Onur Tanrikulu

    SOX9 is a transcription factor linked to cellular plasticity and aggressive behavior in breast cancer. We investigated whether nuclear SOX9 expression correlates with short-term (5-year) survival outcomes in luminal breast cancer. In a retrospective cohort of 60 patients with estrogen receptor-positive invasive breast carcinoma, nuclear SOX9 expression was evaluated via immunohistochemical H-scores (0–300). Survival was analyzed continuously, by median-split dichotomy, and using a 1% nuclear-staining threshold via Kaplan–Meier and Cox regression models. Most tumors were luminal B (73.3%), and 45% were node-positive. Nuclear SOX9 was detected in 51.7% of cases (median positive H-score: 30). Over follow-up, 13 disease-free survival (DFS) and 12 overall survival (OS) events occurred. Continuous H-score did not correlate with clinicopathological variables, DFS (p = 0.576), or OS (p = 0.613). A median-split showed higher 5-year DFS for high-expression tumors (89.7% vs. 74.2%, p = 0.048), but this borderline protective trend was unconfirmed by Cox regression (p = 0.063) or the 1% threshold; ROC analysis showed no discrimination (AUC: 0.34–0.36). Standalone nuclear SOX9 expression has no significant impact on short-term (5-year) prognosis in early-stage luminal breast cancer; extended follow-up is warranted to assess potential late recurrence.

  • Retrospective analysis of glial tumors in light of the 2016 WHO classification of central nervous system tumours diagnosed at a single center between 2005 and 2016

    by Nilay Bakoglu Malinowski, Emel Çakır, İsmail Saygın

    Aims: The 2016 WHO Classification of Tumors of the Central Nervous System introduced a paradigm shift by integrating molecular features with traditional histomorphology. This study aims to retrospectively re-evaluate glial tumor cases from a major tertiary center in light of these evolving classification criteria and provide a baseline for future molecular research. Methods: A retrospective analysis was conducted on 395 glial tumor cases diagnosed at the Karadeniz Technical University Faculty of Medicine, Department of Pathology, between 2005 and 2016. The cases were re-grouped according to the 2016 WHO criteria. Due to the lack of molecular data available during the archival period, cases were categorized under the “Not Otherwise Specified” (NOS) group to establish a comprehensive database. Results: Among the 395 cases analyzed, glioblastoma was identified as the most frequent histological subtype (n=235). A male predominance was observed (56.5%), with mean and median ages of 48.21 and 50 years, respectively. The most common anatomical location was the frontal lobe, and Histological Grade IV was the most prevalent grade. Statistical analyses indicated that demographic and distribution data were consistent with global literature. Conclusion: The findings align with international demographic trends while highlighting the practical challenges of transitioning to molecular-based classifications. While the subsequent 2021 WHO Classification further emphasizes IDH status, "histologically defined" or "NOS" designations remain crucial for regions where molecular testing infrastructure is limited. This study provides a robust archival baseline that facilitates future molecular studies and serves as a reference for glial tumor characterization in resource-constrained settings.

  • Open Access

    Optimization of Scanning Protocol for AI-Integrated Assessment of HER2 Dual Bright-Field In-Situ Hybridization Application in Breast Cancer

    by Nilay Bakoglu Malinowski, Takashi Ohnishi, Emine Cesmecioglu, Dara S. Ross, Tetsuya Tsukamoto, Yukako Yagi

    Accurately determining HER2 status is essential for breast cancer treatment. We developed an AI-integrated in-house application for automated Dual bright-field (BF) in situ hybridization (ISH) analysis on whole slide images (WSIs), although optimal scanning conditions remain unclear. We evaluated scanners and optimized scanning protocols for clinical application. Ten de-identified invasive breast carcinoma cases, with HER2 immunohistochemistry and FISH results, were analyzed using three scanners and six scanning protocols. WSIs scanned by Scanner ‘A’ have 0.12 µm/pixel with 0.95 NA (A1) and 1.2 NA (A2); Scanner ‘B’ have 0.08 µm/pixel (B1); 0.17 µm/pixel (B2); and 0.17 µm/pixel with extended focus (1.4 µm step size and three layers) (B3); Scanner ‘C’ has 0.26 µm/pixel (C1) resolution. Results showed scanning protocols A1, A2, B2, and B3 yielded HER2 gene amplification status and ASCO/CAP ISH group results consistent with manual FISH as the ground truth. However, protocol C demonstrated poor concordance due to nuclei detection failure in six cases. The AI-integrated application achieved the best performance using scanning protocols with optimized resolutions of 0.12 µm/pixel and 0.17 µm/pixel with extended focus. This study highlights the importance of scanner selection in AI-based HER2 assessment and demonstrates that optimized scanning parameters enhance the accuracy and reliability of automated Dual BF ISH analysis.


  • Open Access

    Artificial intelligence-based automated determination in breast and colon cancer and distinction between atypical and typical mitosis using a cloud-based platform

    by Nilay Bakoglu, Emine Cesmecioglu, Hirotsugu Sakamoto, Masao Yoshida, Takashi Ohnishi, Seung-Yi Lee, Lindsey Smith, Yukako Yagi

    Artificial intelligence (AI) technology in pathology has been utilized in many areas and requires supervised machine learning. Notably, the annotations that define the ground truth for the identification of different confusing process pathologies, vary from study to study. In this study, we present our findings in the detection of invasive breast cancer for the IHC/ISH assessment system, along with the automated analysis of each tissue layer, cancer type, etc. in colorectal specimens. Additionally, models for the detection of atypical and typical mitosis in several organs were developed using existing whole-slide image (WSI) sets from other AI projects. All H&E slides were scanned by different scanners with a resolution of 0.12–0.50 μm/pixel, and then uploaded to a cloud-based AI platform. Convolutional neural networks (CNN) training sets consisted of invasive carcinoma, atypical and typical mitosis, and colonic tissue elements (mucosa-epithelium, lamina propria, muscularis mucosa, submucosa, muscularis propria, subserosa, vessels, and lymph nodes). In total, 59 WSIs from 59 breast cases, 217 WSIs from 54 colon cases, and 28 WSIs from 23 different types of tumor cases with relatively higher amounts of mitosis were annotated for the training. The harmonic average of precision and sensitivity was scored as F1 by AI. The final AI models of the Breast Project showed an F1 score of 94.49% for Invasive carcinoma. The mitosis project showed F1 scores of 80.18%, 97.40%, and 97.68% for mitosis, atypical, and typical mitosis layers, respectively. Overall F1 scores for the current results of the colon project were 90.02% for invasive carcinoma, 94.81% for the submucosa layer, and 98.02% for vessels and lymph nodes. After the training and optimization of the AI models and validation of each model, external validators evaluated the results of the AI models via blind-reader tasks. The AI models developed in this study were able to identify tumor foci, distinguish in situ areas, define colonic layers, detect vessels and lymph nodes, and catch the difference between atypical and typical mitosis. All results were exported for integration into our in-house applications for breast cancer and AI model development for both whole-block and whole-slide image-based 3D imaging assessment.


  • Kanserin Moleküler Biyolojisi ve İmmünolojisi

    by Nazmiye Deniz Arslan, Nilay Bakoğlu, Rabiya Altınbaş, Mustafa Yener Uzunoğlu, Ayhan Öz, Beyza Saraçlıgil, Özge Vural, Beslen Göksoy, Ayşe Kutluhan Doğan, Osman Bandırmalı, et al.

    Kanser, insanlığı gerek maddi gerekse manevi açıdan tehdit eden önemli evrensel bir hastalık olmaya devam etmektedir. Bu nedenle kanserin moleküler biyolojisinin anlaşılması ve kanser tedavisine yönelik güçlü prognostik, diyagnostik ve terapötik ajanların geliştirilmesi adına günümüzde büyük çaba sarf edilmektedir. Bu bağlamda, her ne kadar bazı buluşlar ümitlerimizi yeşertse de tanı ve tedaviye yönelik var olan yöntemler ilerlemiş kanser tiplerine karşı savaşta yetersiz kalmaktadır. Son yıllarda insan genom projesinin tamamlanması ile kanserin moleküler temellerinin aydınlatılması adına bilimsel anlamda ciddi adımlar atılmış ve bu adımlar sonucunda heyecan verici güzel sonuçlar elde edilmiştir. Protein kodlayan genlerden kodlanmayan RNA genlerine, epitelyal mezenkimal geçiş mekanizmasından anjiyogeneze, apoptotik hücre ölümünden otofajiye kadar kanserde rol oynayan moleküler birçok yolak ve mekanizma hakkında bugün detaylı bilgilere sahibiz. Ancak bu bilgiler her gün yayınlanan binlerce kanser araştırma makalesi ile gün geçtikçe daha da güncellenmekte ve var olan bazı bilgiler yeni yaklaşımların ortaya çıkması ile geçerliliğini kaybetmektedir.Kanserin moleküler biyolojisinin ve immünolojisin geniş perspektifte anlatıldığı bu kitap, konunun bütünlüğü göz önünde bulundurularak, okuyucunun daha kolay takip edebileceği 5 kısma bölünmüştür. Birinci kısımda, kanserin moleküler temellerine yer verilerek, epidemiyolojisi, histopatolojisi, kanserde onkogen ve tümör baskılayıcı genler ile ilgili genel konulardan bahsedilmiştir. İkinci kısım, Hanahan ve Weinberg’in 2000 yılında yayınladıkları “kanserin ayırt edici özellikleri” makalesinden esinlenerek oluşturulmuş ve bu kısımda kanser hücrelerinin normal hücrelerden ne gibi farklıklarının olduğu geniş bir çerçevede ele alınmıştır. Üçüncü kısımda, özellikle son yıllarda kanser ilişkili yolaklarda önemli işlevleri tanımlanan birçok molekül ile epigenetik düzenleme mekanizmaları güncel verilerle anlatılırken; dördüncü kısımda ise tümör immünolojisi, immün sistemden kaçış mekanizmaları, tümör mikroçevresi ve immünoterapi konularının detaylı olarak ele alındığı kanserin gelişim mekanizmaları ve kişiselleştirilmiş kanser tedavisi için prognostik biyobelirteçler, tümör immüno-baskılanmasını hedefleme stratejileri, gen tedavisi, kanser immünoterapisindeki hücreler, monoklonal antikorların kullanımı gibi daha birçok yenilikçi yaklaşım açıklanmıştır. Son kısım ise klinikte moleküler tanı amaçlı kullanılan veya tedavi planlama stratejilerinde yardımcı olan biyobelirteçlerin anlatıldığı, anti-kanser tedavi yöntemlerin geniş bir şekilde tartışıldığı, gen tedavisi ve kişiselleştirilmiş tıbbın örnekler ile üzerinde durulduğu kısımdır. Alanında uzman birbirinden değerli birçok bilim insanının katkılarıyla siz okuyucular için özenle derlenerek oluşturulan bu kitapta; kanserin moleküler biyolojisi ve immünolojisine güncel bir bakış açısı getirilmesi amaçlanmıştır. Gelişen teknoloji ve artan bilimsel bilginin ışığında bu eserin değerli ve saygın bilim insanlarına fayda sağlaması temennisiyle…